ReviewTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2016
Treatment of lung large cell neuroendocrine carcinoma.
Review in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 63 citations in OpenAlex.
- Phase II study of 1st-line durvalumab and platinum-etoposide in advanced large-cell neuroendocrine lung carcinoma (aLCNEC).Cancer immunology, immunotherapy : CII · 2026Trial
- Exceptional long-term survival in pulmonary large-cell neuroendocrine carcinoma with brain metastases: a case report.Frontiers in oncology · 2026Article
- Effects of different cancer-directed therapies on mortality of patients with stage I pulmonary large cell neuroendocrine carcinoma: a retrospective cohort study based on the SEER database.Translational cancer research · 2025Article
- Pulmonary Large-Cell Neuroendocrine Carcinoma, a Multifaceted Disease-Case Report and Literature Review.Diagnostics (Basel, Switzerland) · 2025Article
- Is CK7 a Prognostic Marker in Pulmonary LCNEC? Evidence from a Limited Cohort Study.Journal of personalized medicine · 2025Article
- Treatment status, survival and gene expression analysis of large-cell neuroendocrine lung carcinoma: a real-world study in China.Therapeutic advances in medical oncology · 2025Article
- Real world results of locally advanced and metastatic lung cancer patients treated with platinum doublet chemotherapy in first line: Moroccan cohort.Translational oncology · 2024Article
- Prognostic factors and predictive models for patients with lung large cell neuroendocrine carcinoma: Based on SEER database.The clinical respiratory journal · 2024Article
- Clinical characteristics, treatment, and outcome of patients with large cell neuroendocrine carcinoma of the lung and brain metastases - data from a tertiary care center.Clinical & experimental metastasis · 2024Article
- Advances in combined neuroendocrine carcinoma of lung cancer.Pathology oncology research : POR · 2024Review
- Concomitant inhibition of PI3K/mTOR signaling pathways boosts antiproliferative effects of lanreotide in bronchopulmonary neuroendocrine tumor cells.Frontiers in pharmacology · 2024Article
- Does subtyping of high-grade pulmonary neuroendocrine carcinomas have an impact on therapy selection?Translational lung cancer research · 2023Article
- Lung Large Cell Neuroendocrine Carcinoma: A Population-Based Retrospective Cohort Study.Journal of clinical medicine · 2023Article
- Enhanced Efficacy of Chemotherapy by Addition of Immune Checkpoint Inhibitors in Stage IV Large Cell Neuroendocrine Carcinoma of the Lung: A Real-World Analysis.Journal of Cancer · 2023Article
- Treatment outcome and prognostic analysis of advanced large cell neuroendocrine carcinoma of the lung.Scientific reports · 2022Article
- Lorlatinib and compound mutations in ALK+ large-cell neuroendocrine lung carcinoma: a case report.Cold Spring Harbor molecular case studies · 2022Article
- Ampullary Large-Cell Neuroendocrine Carcinoma, a Diagnostic Challenge of a Rare Aggressive Neoplasm: A Case Report and Literature Review.Diagnostics (Basel, Switzerland) · 2022Article
- Large Cell Neuroendocrine Carcinoma of the Lung: Current Understanding and Challenges.Journal of clinical medicine · 2022Review
- The Role of Surgery in High-Grade Neuroendocrine Cancer: Indications for Clinical Practice.Frontiers in medicine · 2022Review
- Based on SEER Database: Population Distribution, Survival Analysis, and Prognostic Factors of Organ Metastasis of Lung Large Cell Neuroendocrine Carcinoma.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung large cell neuroendocrine carcinoma (L-LCNEC) is a rare, aggressive, and difficult-to-treat tumor. It is classified as a neuroendocrine subtype of large cell lung carcinoma (LCLC) belonging to the non-small cell lung cancer (NSCLC) group, but it is also included in the neuroendocrine tumor (NET) group. Most of the available data related to its treatment derive from retrospective analyses or small case series. For patients with L-LCNEC, prognosis is generally very poor. In early stages (I-II-III), surgery is recommended but does not seem to be sufficient. Platinum-based adjuvant chemotherapy may be useful while the role of neoadjuvant chemotherapy is still not well defined. In patients with advanced L-LCNEC, the chemotherapy regimens used in SCLC still remain the standard of treatment, but results are not satisfactory. Due to their peculiar clinical and biological features and the lack of literature data, there is an emerging need for a consensus on the best treatment strategy for L-LCNEC and for the identification of new therapeutic options. In this review, we will discuss the key aspects of L-LCNEC management with the aim to clarify the most controversial issues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.